Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 1451 - 1500 of 1864 results
- Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.
- Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive human epidermal growth factor receptor 2-positive metastatic breast cancer.
- Synergistic Growth Inhibition by 9-cis-Retinoic Acid Plus Trastuzumab in Human Hepatocellular Carcinoma Cells.
- Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus.
- Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.
- Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells.
- Cutting Edge: Expression of TNFR2 Defines a Maximally Suppressive Subset of Mouse CD4+CD25+FoxP3+ T Regulatory Cells: Applicability to Tumor-Infiltrating T Regulatory Cells.
- Antiproliferative Activity of IL-27 on Melanoma.
- Enhancement of DNA Vaccine Potency through Coadministration of CIITA DNA with DNA Vaccines via Gene Gun.
- Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model.
- The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment.
- Herpes Virus Oncolytic Therapy Reverses Tumor Immune Dysfunction and Facilitates Tumor Antigen Presentation.
- Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma.
- Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.
- Constitutive expression of IL-12RB2 on human multiple myeloma cells delineates a novel therapeutic target.
- Allovectin-7 therapy in metastatic melanoma.
- Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma.
- Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination.
- Engineering of highly immunogenic long-lived DC vaccines by antiapoptotic protein gene transfer to enhance cancer vaccine potency.
- Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
- Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors.
- Targeting AKT signaling sensitizes cancer to cellular immunotherapy.
- Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies.
- Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer.
- The novel bispecific diabody alphaCD40/alphaCD28 strengthens leukaemic dendritic cell-induced T-cell reactivity.
- Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
- The anti-leukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.
- Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin.
- Is CD133 a marker of metastatic colon cancer stem cells?
- Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
- Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
- Phase II Trial of Pegylated Interferon-alpha2b in Patients with Advanced Renal Cell Carcinoma.
- Prospective phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes in primary lung cancer patients.
- Bifunctional CD22 Ligands Use Multimeric Immunoglobulins as Protein Scaffolds in Assembly of Immune Complexes on B Cells.
- Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival.
- Targeting tumors with LIGHT to generate metastasis-clearing immunity.
- T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.
- Host CD147 blockade by small interfering RNAs suppresses growth of human colon cancer xenografts.
- PPAR-gamma Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors.
- Clinical Efficacy of Taxane-Trastuzumab Combination Regimens for HER-2-Positive Metastatic Breast Cancer.
- UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers.
- NanoFerrite Particle Based Radioimmunonanoparticles: Binding Affinity and In Vivo Pharmacokinetics.
- Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12.
- A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies.
- A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer.
- Adjuvant Radioimmunotherapy Trial with Iodine-131-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody F6 F(ab')2 after Resection of Liver Metastases from Colorectal Cancer.
- Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
- T-Bet Plays a Key Role in NK-Mediated Control of Melanoma Metastatic Disease.
- Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.